NBI-1065890

Phase 2Small molecule

Neurocrine Biosciences

NBI-1065890 is one of 18 small molecule programs targeting Tardive Dyskinesia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Tardive DyskinesiaActive, not recruiting

Tardive DyskinesiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

25 competitors in Tardive Dyskinesia

#DrugCompanyPhaseTrials

Ingrezza

Neurocrine Biosciences

Approved

6 2

Zyprexa

MMODAG GmbH

Approved

2 3

Austedo

Teva

Approved

1 4

Risperdal

WWim Janssens

Approved

1 5

Barhemsys

AAcacia Pharma Ltd

Approved

1 6

Abilify

Otsuka

Approved

1 7

Reminyl

WWim Janssens

Approved

1 8

Eicosapentaenoic Acid

SS.L.A. Pharma AG

Approved

1 9

Inderal

Mylan Pharmaceuticals Inc

Phase 3

1 10

Piracetam

UCB

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Tardive Dyskinesia

NCT07365462

Clinical

Trials by Indication[1]

Tardive Dyskinesia1 trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1065890 in Adult Participants With Tardive Dyskinesia

Recruiting· Neurocrine Biosciences logo

Neurocrine Biosciences·Phase 2·NCT07365462·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NBI-1065890. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NBI-1065890 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NBI-1065890. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Neurocrine Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Neurocrine Biosciences

NBI-1065890

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Tardive Dyskinesia1 trial

References

Drug Info

Quick Facts

Related News